QQ客服 官方微博 反馈留言

	STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC)
	Bruix, Jordi; Takayama, Tadatoshi; Mazzaferro, Vincenzo; Chau, Gar-Yang; Yang, Jiamei; Kudo, Masatoshi; Cai, Jianqiang; Poon, Ronnie Tung-Ping; Han, Kwang-Hyub; Tak, Won-Young
	2014
卷号	32期号:15
ISSN号	0732-183X
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6667416
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Bruix, Jordi,Takayama, Tadatoshi,Mazzaferro, Vincenzo,et al. STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC)[J],2014,32(15).
APA	Bruix, Jordi.,Takayama, Tadatoshi.,Mazzaferro, Vincenzo.,Chau, Gar-Yang.,Yang, Jiamei.,...&Llovet, Josep M..(2014).STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC).,32(15).
MLA	Bruix, Jordi,et al."STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC)".32.15(2014).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。